AMSTERDAM · EST. 2026
Onpeps
PEPTIDE DECISION INTELLIGENCE
Subscribe
← PEPTIDE LIBRARY
RECOVERYGRADE BPROMISING, LIMITED HUMAN DATA

Thymosin Beta-4

Actin-sequestering protein; cell migration and angiogenesis

The naturally occurring 43-amino-acid parent protein that TB-500 is derived from. It has been evaluated in registered trials for corneal and dermal wound healing.

ALSO KNOWN AS Tβ4 · TMSB4X
REGULATORY STATUS · INVESTIGATIONAL

Investigational — studied in clinical trials, not approved. Compounds in this category have not been approved for human use; availability is typically restricted to laboratory research.

§ EVIDENCE BASE
684
PUBLICATIONS
indexed in PubMed
18
REGISTERED TRIALS
listing it as an intervention
15
PHASE 2–4 TRIALS
reached later-stage testing
MECHANISMActin-sequestering protein; cell migration and angiogenesis
CATEGORYRecovery
EVIDENCE GRADEB — Promising, limited human data
STATUSInvestigational — studied in clinical trials, not approved
COUNTS RETRIEVED2026-07-23 · re-run the PubMed query
§ RELATED COMPOUNDS
RECOVERYD
BPC-157
Cytoprotective peptide; angiogenesis and growth-factor signalling
RECOVERYD
KPV
α-MSH C-terminal tripeptide; anti-inflammatory
RECOVERYD
TB-500
Actin-sequestering peptide (Thymosin β4 fragment)
NOT MEDICAL ADVICE

This page summarises how much a compound has been studied. A high publication count is not evidence that something works, is safe, or is legal to obtain where you live. Consult a qualified healthcare provider before acting on anything here.

THE WEEKLY BRIEF

Peptide intelligence, every Monday.

One concise email: the newest research, evidence updates, and quality signals — no hype, no spam.

Onpeps

Our mission is to make peptide research clear, credible, and usable for people who refuse to rely on hype.

EXPLORE
FOLLOW
PEPTIDE INFORMATION YOU CAN VERIFY© 2026 ONPEPS · AMSTERDAM, NETHERLANDS · NOT MEDICAL ADVICE